RECIST (Response Evaluation Criteria in Solid Tumors) guidelines were introduced over twenty years ago to provide a standard for evaluating tumor response, with the goal of maintaining consistency at sites and across sites as well as limiting any site bias. 

With the introduction of intratumoral (IT) immunotherapies, IT immunotherapy RECIST (itRECIST) is proposed to capture data and assess local and systemic responses in a standardized fashion for clinical trials involving these therapies.


CS thumbnail_itRECIST tumor modalityOvercoming Methodology Hurdles
Veristat helped a sponsor write the protocol for a novel treatment that injects engineered exosomes into solid tumors. The application of a set of nuanced response criteria required information collected from injected and non-injected lesions to determine a tumor’s response to the treatment.


itRECIST criteria were used in this scenario to measure changes in tumor size; but as this is a new method for tracking a novel treatment, protocols had to be developed.


Access the Full-Length Case Study

Read the case study to learn more about how our team defined the appropriate methodology for collection and data analysis in this largely untested area of clinical development.





Explore Related Services:



Rolling Review mechanisms and CMAs (Conditional Marketing Authorisations) have made it possible to speed up the approval of treatments against Covid-19

GENESIS BIOMED recently interviewed Xavier Luria, former Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA), and now...

Read More

Shortening Development and Approval Timelines for Novel Medicinal Products

The FDA and EMA offer expedited regulatory approval pathways to accelerate time-to-market for novel therapies intended to treat serious conditions...

Read More

Marketing Application Publishing Best Practices

Effectively managing the publishing of documents required for a marketing application submission can help accelerate the time it takes to bring your...

Read More